Sorivudine

Sorivudine
Systematic (IUPAC) name
1-β-D-arabinofuranosyl-5-[(E)-2-bromovinyl]pyrimidine-2,4(1H,3H)-dione
Clinical data
Trade names Usevir, Brovavir
Routes of
administration
Oral
Pharmacokinetic data
Metabolism Viral thymidine kinase
Excretion Kidney
Identifiers
CAS Number 77181-69-2 YesY
ATC code none
PubChem CID 5282192
ChemSpider 4445384
UNII C7VOZ162LV N
KEGG D01734 YesY
ChEMBL CHEMBL375035 N
Synonyms BV-araU, Bromovinyl araU, 5-Bromovinyl-araU, 5-[(E)-2-bromoethenyl]-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
Chemical data
Formula C11H13BrN2O6
Molar mass 349.14 g/mol
 NYesY (what is this?)  (verify)

Sorivudine (INN), is a thymine analogue antiviral drug, marketed under trade names such as Usevir (Nippon Shoji, Eisai) and Brovavir (BMS).

Pharmacology

Feature

Mechanism of action

Microbiology

Sorivudine is active against most species in the herpesvirus family.

Interactions

Sorivudine interacts strongly and in some cases lethally with fluorouracil (5-FU), its prodrugs and related substances. This is based on the metabolite bromovinyluracil (BVU), which irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase (DPD) which is necessary for inactivating 5-FU. The closely related drug brivudine has the same interaction.[1]

Bromovinyluracil (BVU)

References


This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.